Feasibility of a Novel Wearable Thermal Device for Management of Bothersome Hot Flashes in Patients with Prostate Cancer

Overview

Journal Prostate Cancer Prostatic Dis

Specialties Oncology
Urology

Date 2023 Dec 12

PMID 38086919

Authors

Pamela Peeke

Sonja K Billes

Andrew Vetter

Nader Naghavi

Diana Le

Matthew Smith

Alicia K Morgans

Affiliations

Soon will be listed here.

Abstract

Background: This single-arm prospective study evaluated the feasibility of a novel wrist-worn thermal device that applies cooling to the inside of the wrist for management of bothersome hot flashes in prostate cancer survivors.

Methods: 57 individuals were enrolled and instructed to use the thermal device as needed for management of hot flashes for 4 weeks. The primary outcome was thermal device usage (hours and sessions per day). Additional outcomes included the change in Hot Flash Related Daily Interference Scale (HFRDIS, range 0-10) and Patient Reported Outcomes Measurement Information System Sleep Disturbance 4a (PROMIS SD T-score, range 0-100) and Sleep-Related Impairment 8a (PROMIS SRI T-score, range 0-100). Study procedures were conducted remotely from May to Dec 2021 in the US.

Results: 44 participants completed the study and 39 had retrievable usage data. The mean ± SD age was 67 ± 6 years and 5 ± 5 years since cancer diagnosis. The baseline mean ± SD HFRDIS score of 4.3 ± 2.0 indicated moderate hot flash interference in this population. During the study, participants used the thermal device (mean ± SD) 3.2 ± 2.5 hours/day and 7.6 ± 3.6 sessions/day. Most (67%) participants reported using the device 7 days and 7 nights each week. Statistically significant improvements from baseline at Week 4 were observed for HFRDIS (mean ± SE change: -1.1 ± 0.3), PROMIS SD (-6.0 ± 1.0), and PROMIS SRI (-5.5 ± 1.2) scores (all p < 0.001). The majority (69%) of participants reported that the thermal device was effective at helping them manage hot flashes. No adverse events were reported.

Conclusions: Results support the feasibility of using the thermal device for management of bothersome hot flashes in prostate cancer survivors. Future randomized controlled studies are warranted to evaluate the impact of the thermal device on frequency and severity of hot flashes, sleep quality, fatigue, and overall quality of life.

Citing Articles

Luteinizing hormone-releasing hormone receptor agonists and antagonists in prostate cancer: effects on long-term survival and combined therapy with next-generation hormonal agents.

Zhao J, Chen J, Sun G, Shen P, Zeng H Cancer Biol Med. 2024; 21(11).

PMID: 39718161 PMC: 11667785. DOI: 10.20892/j.issn.2095-3941.2024.0139.

References

Loprinzi C, Dueck A, Khoyratty B, Barton D, Jafar S, Rowland Jr K . A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB). Ann Oncol. 2009; 20(3):542-9. PMC: 2733071. DOI: 10.1093/annonc/mdn644. View

Carpenter J, Guthrie K, Larson J, Freeman E, Joffe H, Reed S . Effect of escitalopram on hot flash interference: a randomized, controlled trial. Fertil Steril. 2012; 97(6):1399-404.e1. PMC: 3367120. DOI: 10.1016/j.fertnstert.2012.03.001. View

Spratt D, Shore N, Sartor O, Rathkopf D, Olivier K . Treating the patient and not just the cancer: therapeutic burden in prostate cancer. Prostate Cancer Prostatic Dis. 2021; 24(3):647-661. PMC: 8384628. DOI: 10.1038/s41391-021-00328-1. View

Schow D, Renfer L, Rozanski T, Thompson I . Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer. South Med J. 1998; 91(9):855-7. DOI: 10.1097/00007611-199809000-00010. View

Reeve B, Tan X, Chen R, Usinger D, Pinheiro L . Symptom and function profiles of men with localized prostate cancer. Cancer. 2018; 124(13):2832-2840. PMC: 6027624. DOI: 10.1002/cncr.31401. View

Gonzalez B, Small B, Cases M, Williams N, Fishman M, Jacobsen P . Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: The role of hot flashes and nocturia. Cancer. 2017; 124(3):499-506. PMC: 5780192. DOI: 10.1002/cncr.31024. View

Robbins R, Cole R, Ejikeme C, Orstad S, Porten S, Salter C . Systematic review of sleep and sleep disorders among prostate cancer patients and caregivers: a call to action for using validated sleep assessments during prostate cancer care. Sleep Med. 2022; 94:38-53. PMC: 9277625. DOI: 10.1016/j.sleep.2022.03.020. View

Ulloa E, Salup R, Patterson S, Jacobsen P . Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer. Psychooncology. 2008; 18(6):598-605. DOI: 10.1002/pon.1427. View

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

10.

Johns M . A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991; 14(6):540-5. DOI: 10.1093/sleep/14.6.540. View

11.

Nishiyama T, Kanazawa S, Watanabe R, Terunuma M, Takahashi K . Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy. Int J Urol. 2004; 11(9):735-41. DOI: 10.1111/j.1442-2042.2004.00896.x. View

12.

Composto J, Leichman E, Luedtke K, Mindell J . Thermal Comfort Intervention for Hot-flash Related Insomnia Symptoms in Perimenopausal and Postmenopausal-aged Women: An Exploratory Study. Behav Sleep Med. 2019; 19(1):38-47. DOI: 10.1080/15402002.2019.1699100. View

13.

Dickinson K, Kupzyk K, Saligan L . Evaluating Dimensions of Fatigue in Men With Prostate Cancer Receiving Radiation Therapy. Cancer Nurs. 2020; 44(1):71-78. PMC: 7321910. DOI: 10.1097/NCC.0000000000000782. View

14.

Dearnaley D, Saltzstein D, Sylvester J, Karsh L, Mehlhaff B, Pieczonka C . The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label,.... Eur Urol. 2020; 78(2):184-192. DOI: 10.1016/j.eururo.2020.03.001. View

15.

Beer T, Benavides M, Emmons S, Hayes M, Liu G, Garzotto M . Acupuncture for hot flashes in patients with prostate cancer. Urology. 2010; 76(5):1182-8. PMC: 2928879. DOI: 10.1016/j.urology.2010.03.033. View

16.

Zimmerman Y, Frydenberg M, van Poppel H, Jeroen A van Moorselaar R, Roos E, Somford D . Estetrol Prevents Hot Flushes and Improves Quality of Life in Patients with Advanced Prostate Cancer Treated with Androgen Deprivation Therapy: The PCombi Study. Eur Urol Open Sci. 2022; 45:59-67. PMC: 9637725. DOI: 10.1016/j.euros.2022.09.006. View

17.

Ligibel J, Bohlke K, May A, Clinton S, Demark-Wahnefried W, Gilchrist S . Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline. J Clin Oncol. 2022; 40(22):2491-2507. DOI: 10.1200/JCO.22.00687. View

18.

Carpenter J . The Hot Flash Related Daily Interference Scale: a tool for assessing the impact of hot flashes on quality of life following breast cancer. J Pain Symptom Manage. 2001; 22(6):979-89. DOI: 10.1016/s0885-3924(01)00353-0. View

19.

Toohey K, Chapman M, Rushby A, Urban K, Ingham G, Singh B . The effects of physical exercise in the palliative care phase for people with advanced cancer: a systematic review with meta-analysis. J Cancer Surviv. 2022; 17(2):399-415. DOI: 10.1007/s11764-021-01153-0. View

20.

Moraska A, Atherton P, Szydlo D, Barton D, Stella P, Rowland Jr K . Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CB. J Support Oncol. 2010; 8(3):128-32. PMC: 3075822. View